Literature DB >> 10714912

Efficacy and safety of oral estriol for managing postmenopausal symptoms.

K Takahashi1, A Manabe, M Okada, H Kurioka, H Kanasaki, K Miyazaki.   

Abstract

OBJECTIVE: to assess the therapeutic efficacy and safety of oral estriol for the treatment of climacteric symptoms in postmenopausal women.
METHODS: 68 postmenopausal women with climacteric symptoms received oral estriol, 2 mg/day, daily for 12 months. We evaluated the degree of climacteric complaints with estriol therapy; serum levels of gonadotropins, estradiol (E2) and lipids; biochemical markers of bone metabolism; blood pressure; and side effects both at baseline and during treatment. Climacteric symptoms were assessed according to the menopausal index (MI), a version of the Kupperman index that had been modified for Japanese women.
RESULTS: oral estriol therapy significantly reduced total MI scores. The greatest relief was noted for hot flushes, night sweats, and insomnia. Estriol treatment significantly lowered serum follicle stimulating hormone (FSH) and luteinizing hormone (LH) concentrations but did not affect any of the other parameters (lipids, bone, liver and blood pressure) during the study period. Slightly vaginal bleeding occurred in 14.3% of those who underwent natural menopausal women. Histologic evaluation of the endometrium and ultrasound assessment of the breasts following 12 months of estriol treatment found normal results in all women.
CONCLUSION: Estriol is a safe and effective alternative for relieving climacteric symptoms in postmenopausal Japanese women.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10714912     DOI: 10.1016/s0378-5122(99)00108-5

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  8 in total

1.  Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis.

Authors:  Noriko Itoh; Roy Kim; Mavis Peng; Emma DiFilippo; Hadley Johnsonbaugh; Allan MacKenzie-Graham; Rhonda R Voskuhl
Journal:  J Neuroimmunol       Date:  2016-10-03       Impact factor: 3.478

Review 2.  The importance of studying sex differences in disease: The example of multiple sclerosis.

Authors:  Lisa C Golden; Rhonda Voskuhl
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

3.  Estrogen treatment in multiple sclerosis.

Authors:  Stefan M Gold; Rhonda R Voskuhl
Journal:  J Neurol Sci       Date:  2009-06-18       Impact factor: 3.181

Review 4.  Neuroendocrine immunoregulation in multiple sclerosis.

Authors:  Nathalie Deckx; Wai-Ping Lee; Zwi N Berneman; Nathalie Cools
Journal:  Clin Dev Immunol       Date:  2013-12-08

5.  Oestrogen receptor β ligand acts on CD11c+ cells to mediate protection in experimental autoimmune encephalomyelitis.

Authors:  Roy Y Kim; Darian Mangu; Alexandria S Hoffman; Rojan Kavosh; Eunice Jung; Noriko Itoh; Rhonda Voskuhl
Journal:  Brain       Date:  2018-01-01       Impact factor: 13.501

6.  Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis.

Authors:  Riley Bove; Charles C White; Kathryn C Fitzgerald; Tanuja Chitnis; Lori Chibnik; Alberto Ascherio; Kassandra L Munger
Journal:  Neurology       Date:  2016-09-07       Impact factor: 9.910

Review 7.  Prevention and treatment of venous thromboembolism during HRT: current perspectives.

Authors:  Hannelore Rott
Journal:  Int J Gen Med       Date:  2014-09-01

Review 8.  Off-label use of hormones as an antiaging strategy: a review.

Authors:  Nikolaos Samaras; Maria-Aikaterini Papadopoulou; Dimitrios Samaras; Filippo Ongaro
Journal:  Clin Interv Aging       Date:  2014-07-23       Impact factor: 4.458

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.